Exclusive Summary

• - Global patents expired around 2011–2012 with broad generic entry, enabling rapid distribution-led launches.
• - ~2.3M new breast cancer cases and ~7.8M 5-year prevalence globally; ~70% are HR+, requiring long-term endocrine therapy and ensuring steady demand.
• - Included in the WHO Essential Medicines List; NCCN/ESMO endorse AIs as standard first-line/adjuvant therapy and as the backbone with CDK4/6 inhibitors.
• - Highly genericized market, but differentiation is feasible via Zone IVb stability, robust CTD/BE package, and reliable high-volume supply.
• - Very low daily dose (2.5 mg) keeps COGS down; generics typically >90% cheaper than originator, ideal for tenders and cash-pay segments.